Author details

Full Name

Catherine Alcaide-Loridan

Affiliation

Institute of Bioengineering, Miguel Hernandez University of Elche

ORCID

Career Start Year

1989

Papers

H Index

Expertise

CM4AI Collaborator

Antoine Forget (CM4AI)

PMID	Paper Title	Journal Title	Published Year
37467976	Geological context and human exposures to element mixtures in mining and agricultural settings in Colombia.	Sci Total Environ	2023
37175834	Reference Values on Children's Hair for 28 Elements (Heavy Metals and Essential Elements) Based on a Pilot Study in a Representative Non-Contaminated Local Area.	Int J Mol Sci	2023
29312393	Identification and Molecular Characterization of the Chloroplast Targeting Domain of <i>Turnip yellow mosaic virus</i> Replication Proteins.	Front Plant Sci	2017
22406932	Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells.	J Cancer Res Clin Oncol	2012
23039186	LFA-1 and ICAM-1 expression induced during melanoma-endothelial cell co-culture favors the transendothelial migration of melanoma cell lines in vitro.	BMC Cancer	2012
22802610	Ubiquitin and plant viruses, let's play together!	Plant Physiol	2012
22454190	Plasticity of melanoma cells induced by neural cell crest conditions and three-dimensional growth.	Melanoma Res	2012
22487681	PHF19 and Akt control the switch between proliferative and invasive states in melanoma.	Cell Cycle	2012
21466663	Junctional adhesion molecules are required for melanoma cell lines transendothelial migration in vitro.	Pigment Cell Melanoma Res	2011
21911602	Hypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cells.	J Immunol	2011
21526207	Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function.	PLoS One	2011
19574933	Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis.	Melanoma Res	2009
17719638	The context of HLA-DR/CD18 complex in the plasma membrane governs HLA-DR-derived signals in activated monocytes.	Mol Immunol	2008
18234961	Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis.	Mol Cancer Res	2008
17304627	Pathologic expression of MHC class II is driven by mitogen-activated protein kinases.	Eur J Immunol	2007
14973505	Defective class II transactivator expression in a B lymphoma cell line.	Leukemia	2004
15577315	Class II transactivator (CIITA) isoform expression and activity in melanoma.	Melanoma Res	2004
15302575	HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells.	Exp Cell Res	2004
14574520	Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course.	Immunogenetics	2003
11978778	MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.	Int Immunol	2002
12147620	Isoforms of the class II transactivator protein.	Int Immunol	2002
11418637	Constitutive expression of MHC class II genes in melanoma cell lines results from the transcription of class II transactivator abnormally initiated from its B cell-specific promoter.	J Immunol	2001
11313409	Uncoordinated HLA-D gene expression in a RFXANK-defective patient with MHC class II deficiency.	J Immunol	2001
11466404	Mutation in the class II trans-activator leading to a mild immunodeficiency.	J Immunol	2001
10663561	Defective MHC class II expression in an MHC class II deficiency patient is caused by a novel deletion of a splice donor site in the MHC class II transactivator gene.	Immunogenetics	2000
10803838	Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B.	Immunogenetics	2000
10614011	Differential expression of MHC class II isotype chains.	Microbes Infect	1999
9716648	CIITA B-cell-specific promoter suppression in MHC class II-silenced cell hybrids.	Immunogenetics	1998
9002447	Isolation of a B-cell-specific promoter for the human class II transactivator.	Immunogenetics	1997
8606055	The RAG cell line defines a new complementation group of MHC class II deficiency.	Immunogenetics	1996
7557474	Transfer of yeast artificial chromosomes into mammalian cells and comparative study of their integrity.	Gene	1995
1665572	The recombinant human interferon-gamma receptor is fully functional in a human x murine hybrid containing human chromosome 21.	Res Immunol	1991
1684564	Cytogenetic and molecular analysis of a de novo tandem duplication of chromosome 21.	Hum Genet	1991
1906174	Human chromosome 16 encodes a factor involved in induction of class II major histocompatibility antigens by interferon gamma.	Proc Natl Acad Sci U S A	1991
2532616	Human interferon gamma receptor 1 (IFNGR1) gene maps to chromosome region 6q23-6q24.	Hum Genet	1989
2556800	Characterization of human IFN-gamma response using somatic cell hybrids of hematopoietic and nonhematopoietic origin.	Somat Cell Mol Genet	1989

1 - 36 of 36

Maggie Cam

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 2005

Number of shared co-authors 0

Dorian LaTocha

Knight Cancer Institute, Oregon Health & Science University

Career Start Year 2000

Number of shared co-authors 0

Nevila Hyka-Nouspikel

Centre Medical Universitaire

Career Start Year 1998

Number of shared co-authors 0

Alexander Tarakhovsky

The Rockefeller University

Career Start Year 1994

Number of shared co-authors 0

Otavia L Caballero

Ludwig Institute for Cancer Research Ltd.

Career Start Year 1993

Number of shared co-authors 0

Claudia Giachino

University of Turin

Career Start Year 1991

Number of shared co-authors 0

Wenbin Wei

Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield

Career Start Year 1991

Number of shared co-authors 0

Abdel G Elkahloun

National Human Genome Research Institute

Career Start Year 1990

Number of shared co-authors 0

Dirk Geerts

Amsterdam University Medical Center

Career Start Year 1989

Number of shared co-authors 0

Kaoru Saijo

Helen Wills Neuroscience Institute, University of California berkeley

Career Start Year 1988

Number of shared co-authors 0

Luiz F L Reis

Universidade Federal de Santa Maria

Career Start Year 1988

Number of shared co-authors 0

Thomas Decker

University of Vienna

Career Start Year 1985

Number of shared co-authors 0

Karen Cerosaletti

Center for Translational Immunology

Career Start Year 1985

Number of shared co-authors 0

Tarik M??r??y

Institut de recherches cliniques de Montreal

Career Start Year 1985

Number of shared co-authors 0

Colin R Goding

Ludwig Institute for Cancer Research, University of Oxford

Career Start Year 1983

Number of shared co-authors 0

Bertram Opalka

University Hospital Essen.

Career Start Year 1982

Number of shared co-authors 0

Lionel Feigenbaum

Science Applications International Corporation/Frederick

Career Start Year 1981

Number of shared co-authors 0

Brian Seed

Center for Computational and Integrative Biology, Massachusetts General Hospital

Career Start Year 1980

Number of shared co-authors 0

Robert E Lewis

University of Nebraska Medical Center

Career Start Year 1980

Number of shared co-authors 0

Wolfgang Holter

St. Anna Children's Hospital, Medical University of Vienna

Career Start Year 1980

Number of shared co-authors 0

Alexander Kamb

Inc. 30301 Agoura Rd.

Career Start Year 1979

Number of shared co-authors 0

Charles Auffray

European Institute for Systems Biology and Medicine

Career Start Year 1978

Number of shared co-authors 1

Brian Van Ness

University of Minnesota

Career Start Year 1978

Number of shared co-authors 0

Jeremy M Boss

Emory University School of Medicine

Career Start Year 1976

Number of shared co-authors 0

Howard A Young

Center for Cancer Research, National Cancer Institute

Career Start Year 1975

Number of shared co-authors 0

Yuichi Obata

RIKEN BioResource Research Center

Career Start Year 1975

Number of shared co-authors 0

Louise C Showe

The Wistar Institute

Career Start Year 1975

Number of shared co-authors 0

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Career Start Year 1974

Number of shared co-authors 0

Hartmut Land

University of Rochester Medical Center, Wilmot Cancer Institute

Career Start Year 1974

Number of shared co-authors 0

Tak W Mak

Princess Margaret Cancer Centre, University Health Network

Career Start Year 1970

Number of shared co-authors 0

row(s) 1 - 30 of 30